Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma

Diffuse glioma constitutes 28% of primary brain tumors. Until recently morphologic appearance was the only criterion for classifying these tumors. However, WHO 2016 incorporates molecular information in the primary diagnosis of gliomas such as Isocitrate dehydrogenase 1 (IDH1), Alpha thalassemia/men...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical and experimental pathology 2024-01, Vol.17 (1), p.13-21
Hauptverfasser: Panambur, Chandni Bhandary, Ramamoorthy, Subhashini, Srinivas, Bheemanathi Hanuman, Jinkala, Sree Rekha, Verma, Surendar Kumar, Sasidharan, Gopalakrishnan Madhavan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 21
container_issue 1
container_start_page 13
container_title International journal of clinical and experimental pathology
container_volume 17
creator Panambur, Chandni Bhandary
Ramamoorthy, Subhashini
Srinivas, Bheemanathi Hanuman
Jinkala, Sree Rekha
Verma, Surendar Kumar
Sasidharan, Gopalakrishnan Madhavan
description Diffuse glioma constitutes 28% of primary brain tumors. Until recently morphologic appearance was the only criterion for classifying these tumors. However, WHO 2016 incorporates molecular information in the primary diagnosis of gliomas such as Isocitrate dehydrogenase 1 (IDH1), Alpha thalassemia/mental retardation syndrome X inked (ATRX) as well as 1p/19q codeletion on FISH. In a resource-limited setup where FISH is not available, Alpha internexin (INA) has been suggested as a surrogate IHC marker. Cross-sectional study conducted in the Department of Pathology for two years. Tissue blocks and clinical as well as radiological details were obtained from departmental archives. After assessing the morphologic details, routine IHC markers such as GFAP, Ki67 and P53 along with molecular markers like IDH-1, ATRX, and lNA were applied. Out of 55 cases of diffuse glioma, 23 cases of astrocytoma and 32 cases of oligodendroglioma with an overall mean age of presentation of 41.49 ± 12.47 years. IDH-1 expression among diffuse glioma was 89.1% in our study. Alteration in the ATRX gene expression was observed in 95.7% of astrocytomas. 75% of oligodendrogliomas expressed INA with no significant difference in expression between the two grades. Based on the algorithmic approach using molecular surrogate markers, diffuse gliomas were categorized into six distinct groups. IDH-mutant, ATRX loss of expression astrocytoma and IDH-mutant, INA positive oligodendroglioma are two categories that do not require further molecular testing. This comprises 72.7% of the cases and these do not warrant further workup. Implementation of combined phenotypic-genotypic diagnosis with the use of histomorphology and immunohistochemical surrogates for molecular genetic alterations will yield more homogeneous and narrowly defined diagnostic entities which will provide better prognostication and definitive treatment. It also is cost-effective in a resource-limited setup.
doi_str_mv 10.62347/AJCP7971
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10839248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2923327180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-b646af148c9d4ace955f0c139a802903e92e73ea068ccda7e857e36a5427cae53</originalsourceid><addsrcrecordid>eNpVkUtP3TAQhS0EAgos-APIS7q4rR-JHa_Q1VVfCIkuytoanHFi5MQXO6l0-fWNeImuZjTz6cwZHULOOfuihKz01_X15rc2mu-RY26kWgkl6v0P_RH5VMoDY4qLih2SI9lIIbiWxySvY5dymPohOArbbU7gejpPIYanMHa0D2VKMXU7CmNLwzDMY3qeuR6HpeYd9SnTqUfq5pxxnKiLUErwwcEU0kiTp23wfi5IuxjSAKfkwEMsePZaT8jd929_Nj9XN7c_fm3WNysnlJpW96pS4HnVONNW4NDUtWeOSwMNE4ZJNAK1RGCqca4FjU2tUSqoK6EdYC1PyNWL7na-H7B1i7cM0W5zGCDvbIJg_9-Mobdd-ms5a6QRVbMoXL4q5PQ4Y5ns8rLDGGHENBcrjJBSaN6wBf38grqcSsno3-9wZp9Dsm8hLezFR2Pv5Fsq8h9pV5D2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2923327180</pqid></control><display><type>article</type><title>Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Panambur, Chandni Bhandary ; Ramamoorthy, Subhashini ; Srinivas, Bheemanathi Hanuman ; Jinkala, Sree Rekha ; Verma, Surendar Kumar ; Sasidharan, Gopalakrishnan Madhavan</creator><creatorcontrib>Panambur, Chandni Bhandary ; Ramamoorthy, Subhashini ; Srinivas, Bheemanathi Hanuman ; Jinkala, Sree Rekha ; Verma, Surendar Kumar ; Sasidharan, Gopalakrishnan Madhavan</creatorcontrib><description>Diffuse glioma constitutes 28% of primary brain tumors. Until recently morphologic appearance was the only criterion for classifying these tumors. However, WHO 2016 incorporates molecular information in the primary diagnosis of gliomas such as Isocitrate dehydrogenase 1 (IDH1), Alpha thalassemia/mental retardation syndrome X inked (ATRX) as well as 1p/19q codeletion on FISH. In a resource-limited setup where FISH is not available, Alpha internexin (INA) has been suggested as a surrogate IHC marker. Cross-sectional study conducted in the Department of Pathology for two years. Tissue blocks and clinical as well as radiological details were obtained from departmental archives. After assessing the morphologic details, routine IHC markers such as GFAP, Ki67 and P53 along with molecular markers like IDH-1, ATRX, and lNA were applied. Out of 55 cases of diffuse glioma, 23 cases of astrocytoma and 32 cases of oligodendroglioma with an overall mean age of presentation of 41.49 ± 12.47 years. IDH-1 expression among diffuse glioma was 89.1% in our study. Alteration in the ATRX gene expression was observed in 95.7% of astrocytomas. 75% of oligodendrogliomas expressed INA with no significant difference in expression between the two grades. Based on the algorithmic approach using molecular surrogate markers, diffuse gliomas were categorized into six distinct groups. IDH-mutant, ATRX loss of expression astrocytoma and IDH-mutant, INA positive oligodendroglioma are two categories that do not require further molecular testing. This comprises 72.7% of the cases and these do not warrant further workup. Implementation of combined phenotypic-genotypic diagnosis with the use of histomorphology and immunohistochemical surrogates for molecular genetic alterations will yield more homogeneous and narrowly defined diagnostic entities which will provide better prognostication and definitive treatment. It also is cost-effective in a resource-limited setup.</description><identifier>ISSN: 1936-2625</identifier><identifier>EISSN: 1936-2625</identifier><identifier>DOI: 10.62347/AJCP7971</identifier><identifier>PMID: 38322173</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>International journal of clinical and experimental pathology, 2024-01, Vol.17 (1), p.13-21</ispartof><rights>IJCEP Copyright © 2024.</rights><rights>IJCEP Copyright © 2024 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-b646af148c9d4ace955f0c139a802903e92e73ea068ccda7e857e36a5427cae53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10839248/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10839248/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38322173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Panambur, Chandni Bhandary</creatorcontrib><creatorcontrib>Ramamoorthy, Subhashini</creatorcontrib><creatorcontrib>Srinivas, Bheemanathi Hanuman</creatorcontrib><creatorcontrib>Jinkala, Sree Rekha</creatorcontrib><creatorcontrib>Verma, Surendar Kumar</creatorcontrib><creatorcontrib>Sasidharan, Gopalakrishnan Madhavan</creatorcontrib><title>Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma</title><title>International journal of clinical and experimental pathology</title><addtitle>Int J Clin Exp Pathol</addtitle><description>Diffuse glioma constitutes 28% of primary brain tumors. Until recently morphologic appearance was the only criterion for classifying these tumors. However, WHO 2016 incorporates molecular information in the primary diagnosis of gliomas such as Isocitrate dehydrogenase 1 (IDH1), Alpha thalassemia/mental retardation syndrome X inked (ATRX) as well as 1p/19q codeletion on FISH. In a resource-limited setup where FISH is not available, Alpha internexin (INA) has been suggested as a surrogate IHC marker. Cross-sectional study conducted in the Department of Pathology for two years. Tissue blocks and clinical as well as radiological details were obtained from departmental archives. After assessing the morphologic details, routine IHC markers such as GFAP, Ki67 and P53 along with molecular markers like IDH-1, ATRX, and lNA were applied. Out of 55 cases of diffuse glioma, 23 cases of astrocytoma and 32 cases of oligodendroglioma with an overall mean age of presentation of 41.49 ± 12.47 years. IDH-1 expression among diffuse glioma was 89.1% in our study. Alteration in the ATRX gene expression was observed in 95.7% of astrocytomas. 75% of oligodendrogliomas expressed INA with no significant difference in expression between the two grades. Based on the algorithmic approach using molecular surrogate markers, diffuse gliomas were categorized into six distinct groups. IDH-mutant, ATRX loss of expression astrocytoma and IDH-mutant, INA positive oligodendroglioma are two categories that do not require further molecular testing. This comprises 72.7% of the cases and these do not warrant further workup. Implementation of combined phenotypic-genotypic diagnosis with the use of histomorphology and immunohistochemical surrogates for molecular genetic alterations will yield more homogeneous and narrowly defined diagnostic entities which will provide better prognostication and definitive treatment. It also is cost-effective in a resource-limited setup.</description><subject>Original</subject><issn>1936-2625</issn><issn>1936-2625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkUtP3TAQhS0EAgos-APIS7q4rR-JHa_Q1VVfCIkuytoanHFi5MQXO6l0-fWNeImuZjTz6cwZHULOOfuihKz01_X15rc2mu-RY26kWgkl6v0P_RH5VMoDY4qLih2SI9lIIbiWxySvY5dymPohOArbbU7gejpPIYanMHa0D2VKMXU7CmNLwzDMY3qeuR6HpeYd9SnTqUfq5pxxnKiLUErwwcEU0kiTp23wfi5IuxjSAKfkwEMsePZaT8jd929_Nj9XN7c_fm3WNysnlJpW96pS4HnVONNW4NDUtWeOSwMNE4ZJNAK1RGCqca4FjU2tUSqoK6EdYC1PyNWL7na-H7B1i7cM0W5zGCDvbIJg_9-Mobdd-ms5a6QRVbMoXL4q5PQ4Y5ns8rLDGGHENBcrjJBSaN6wBf38grqcSsno3-9wZp9Dsm8hLezFR2Pv5Fsq8h9pV5D2</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Panambur, Chandni Bhandary</creator><creator>Ramamoorthy, Subhashini</creator><creator>Srinivas, Bheemanathi Hanuman</creator><creator>Jinkala, Sree Rekha</creator><creator>Verma, Surendar Kumar</creator><creator>Sasidharan, Gopalakrishnan Madhavan</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma</title><author>Panambur, Chandni Bhandary ; Ramamoorthy, Subhashini ; Srinivas, Bheemanathi Hanuman ; Jinkala, Sree Rekha ; Verma, Surendar Kumar ; Sasidharan, Gopalakrishnan Madhavan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-b646af148c9d4ace955f0c139a802903e92e73ea068ccda7e857e36a5427cae53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Panambur, Chandni Bhandary</creatorcontrib><creatorcontrib>Ramamoorthy, Subhashini</creatorcontrib><creatorcontrib>Srinivas, Bheemanathi Hanuman</creatorcontrib><creatorcontrib>Jinkala, Sree Rekha</creatorcontrib><creatorcontrib>Verma, Surendar Kumar</creatorcontrib><creatorcontrib>Sasidharan, Gopalakrishnan Madhavan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Panambur, Chandni Bhandary</au><au>Ramamoorthy, Subhashini</au><au>Srinivas, Bheemanathi Hanuman</au><au>Jinkala, Sree Rekha</au><au>Verma, Surendar Kumar</au><au>Sasidharan, Gopalakrishnan Madhavan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma</atitle><jtitle>International journal of clinical and experimental pathology</jtitle><addtitle>Int J Clin Exp Pathol</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>17</volume><issue>1</issue><spage>13</spage><epage>21</epage><pages>13-21</pages><issn>1936-2625</issn><eissn>1936-2625</eissn><abstract>Diffuse glioma constitutes 28% of primary brain tumors. Until recently morphologic appearance was the only criterion for classifying these tumors. However, WHO 2016 incorporates molecular information in the primary diagnosis of gliomas such as Isocitrate dehydrogenase 1 (IDH1), Alpha thalassemia/mental retardation syndrome X inked (ATRX) as well as 1p/19q codeletion on FISH. In a resource-limited setup where FISH is not available, Alpha internexin (INA) has been suggested as a surrogate IHC marker. Cross-sectional study conducted in the Department of Pathology for two years. Tissue blocks and clinical as well as radiological details were obtained from departmental archives. After assessing the morphologic details, routine IHC markers such as GFAP, Ki67 and P53 along with molecular markers like IDH-1, ATRX, and lNA were applied. Out of 55 cases of diffuse glioma, 23 cases of astrocytoma and 32 cases of oligodendroglioma with an overall mean age of presentation of 41.49 ± 12.47 years. IDH-1 expression among diffuse glioma was 89.1% in our study. Alteration in the ATRX gene expression was observed in 95.7% of astrocytomas. 75% of oligodendrogliomas expressed INA with no significant difference in expression between the two grades. Based on the algorithmic approach using molecular surrogate markers, diffuse gliomas were categorized into six distinct groups. IDH-mutant, ATRX loss of expression astrocytoma and IDH-mutant, INA positive oligodendroglioma are two categories that do not require further molecular testing. This comprises 72.7% of the cases and these do not warrant further workup. Implementation of combined phenotypic-genotypic diagnosis with the use of histomorphology and immunohistochemical surrogates for molecular genetic alterations will yield more homogeneous and narrowly defined diagnostic entities which will provide better prognostication and definitive treatment. It also is cost-effective in a resource-limited setup.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>38322173</pmid><doi>10.62347/AJCP7971</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-2625
ispartof International journal of clinical and experimental pathology, 2024-01, Vol.17 (1), p.13-21
issn 1936-2625
1936-2625
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10839248
source PubMed Central; EZB Electronic Journals Library
subjects Original
title Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A36%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Algorithmic%20approach%20utilizing%20histology%20and%20immunohistochemistry%20for%20the%20current%20classification%20of%20diffuse%20glioma&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20pathology&rft.au=Panambur,%20Chandni%20Bhandary&rft.date=2024-01-01&rft.volume=17&rft.issue=1&rft.spage=13&rft.epage=21&rft.pages=13-21&rft.issn=1936-2625&rft.eissn=1936-2625&rft_id=info:doi/10.62347/AJCP7971&rft_dat=%3Cproquest_pubme%3E2923327180%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2923327180&rft_id=info:pmid/38322173&rfr_iscdi=true